ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1981

Developing International Consensus Definitions Of Improvement For Adult and Juvenile Dermatomyositis and Polymyositis

Saad Feroz1, Nicolino. Ruperto2, Jiri Vencovsky3, Peter A. Lachenbruch1, Brian Erman4, Adam Huber5, Brian M. Feldman6, Ingrid E. Lundberg7, Angela Pistorio8, Howard Rockette9, Frederick W. Miller1, Rohit Aggarwal10, Lisa G. Rider1, for The ACR-EULAR Myositis Response Criteria Project Group11, Angelo Ravelli12, Clarissa Pilkington13 and Sheila K. Oliveira14, 1Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, 2PRINTO, IRCCS G. Gaslini, Genoa, Italy, 3Institute of Rheumatology, Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 4SRA International, Research Triangle Park, NC, 5IWK Health Centre, Halifax, NS, Canada, 6Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, 7Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, 8PRINTO, Genoa, Italy, 9University of Pittsburgh, Pittsburgh, PA, 10Medicine / Rheumatology, University of Pittsburgh, Pittsburgh, PA, 11NIEHS, NIH, Bethesda, MD, 12Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy, 13Rheumatology Department, Great Ormond Street Hospital, London, United Kingdom, 14Pediatric Rheumatology, Instituto de Pediatria e Puericultura Martagão Gesteira (IPPMG) da Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Clinical Response, dermatomyositis, juvenile dermatomyositis, Myositis and outcome measures

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: ARHP Imaging of Rheumatic Disease: Research Methodology

Session Type: Abstract Submissions (ARHP)

Background/Purpose:

IMACS and PRINTO have developed preliminary core set activity measures and definitions of improvement (DOIs). However, these were developed from small and partially retrospective data sets. The current project will develop and further validate DOIs for adult and juvenile dermatomyositis (DM) and polymyositis (PM), and the first definition of major clinical improvement for use in therapeutic trials.

Methods: A repository of 8 natural history studies and 8 clinical trials in DM/PM was used to create 270 adult and 299 pediatric patient profiles consisting of core set activity measures on two visits.  Clinical experts completed a questionnaire on their experience with the core set measures and care of myositis patients. Experts, randomized into survey groups based on experience, rated the degree of improvement in patient profiles. 

Results:

Sixty-six adult specialists (39 rheumatologist, 11 neurologists, 7 dermatologists, 7 other), saw an average of 82 adult DM/PM patients and practiced an average of 18.6 years. Fifty-two percent of adult experts had experience with 5 of 6 core set measures. Sixty-nine pediatric specialists, primarily rheumatologists, saw an average of 28 juvenile DM patients and practiced an average of 19.7 years. Forty-nine percent had experience with all core set measures and 34% had experience with 7 or 8 of 9 measures. Adult and pediatric experts had participated in an average of 1.5 trials utilizing IMACs measures; pediatric experts participated in 1 trial using PRINTO measures.  Patient profiles indicated a moderate degree of activity (median MD global activity of 2 and 5, Patient/parent global activity of 5 and 4.9, MMT-8 score of 70 and 54, Extra-Muscular global activity of 1.7 in adult and 5.0 in pediatric profiles).  Profiles varied in their degree of improvement based on the IMACS preliminary DOI (52% adult and 77% of pediatric profiles met DOI20%, 18% adult and 54% of pediatric profiles met DOI60%, and 48% adult and 23% of pediatric profiles were not improved by the DOI).   Four-hundred-seven DOIs have been drafted to be tested for sensitivity and specificity, based on the number of measures and the degree of change corresponding to consensus clinical improvement, and inclusion of FDA’s recommendation to incorporate patient-reported outcomes. Additional DOIs will be created by logistic regression analysis of the ratings of patient profiles. The top performing DOIs will be externally validated with data from 4 randomized controlled trials.

Conclusion: A DOI for minimal and major clinical response will be developed and fully validated for adult and juvenile DM/PM using large natural history and clinical trial datasets.  These internationally accepted consensus DOIs should facilitate new trials and enhance development of future therapies for myositis patients.


Disclosure:

S. Feroz,
None;

N. Ruperto,

ACR-EULAR, The UK Myositis Support Group, Cure JM Foundation, and The Myositis Association,

2;

J. Vencovsky,

ACR-EULAR, the UK Myositis Support Group, Cure JM Foundation, The Myositis Association,

2;

P. A. Lachenbruch,

ACR-EULAR, NIEHS,

5;

B. Erman,

NIEHS,

9;

A. Huber,
None;

B. M. Feldman,
None;

I. E. Lundberg,

Brisol Myers Squibb,

2,

Novartis Pharmaceutical Corporation,

5;

A. Pistorio,

ACR-EULAR,

2;

H. Rockette,

ACR-EULAR, NIEHS,

2;

F. W. Miller,

ACR-EULAR, NIEHS, NIH Office of Rare Diseases, NIAMS, the UK Myositis Support Group, Cure JM Foundation, The Myositis Association,

2;

R. Aggarwal,

ACR-EULAR, the UK Myositis Support Group, Cure JM Foundation, The Myositis Association,

2;

L. G. Rider,

ACR-EULAR, NIEHS, NIH Office of Rare Diseases, NIAMS, the UK Myositis Support Group, Cure JM Foundation, The Myositis Association,

2;

F. T. ACR-EULAR Myositis Response Criteria Project Group,
None;

A. Ravelli,
None;

C. Pilkington,

Great Ormond Street Hospital Charity ,

2,

Great Ormond Street Hospital Trust,

3,

UCB SLE trial,

5,

President of British Society for Paediatric and Adolescent Rheumatology,

6;

S. K. Oliveira,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/developing-international-consensus-definitions-of-improvement-for-adult-and-juvenile-dermatomyositis-and-polymyositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology